| Literature DB >> 27355000 |
Joseph T Santoso1, Edmundo Yibirin2, Mary Crigger1, Jim Wan3, Adam C ElNaggar4.
Abstract
PURPOSE: Identify the incidence and factors contributing to the termination of gynecologic patient-physician relationships.Entities:
Keywords: Outcomes; Patient-centered care; Patient-physician relationship; Qualitative research
Year: 2016 PMID: 27355000 PMCID: PMC4909815 DOI: 10.1016/j.gore.2016.05.011
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Demographics of terminated and retained patients.
| Factor | Terminated patients N (%) | Retained patients N (%) | OR (95% CI) |
|---|---|---|---|
| N | 123 | 8728 | |
| Age (median, range) | 47 (19–94) | 52 (11 − 102) | |
| Race | |||
| African American | 80 (65) | 2873 (32.9) | 3.8 (2.6–5.5) |
| White | 42 (34.1) | 5363 (61.4) | 0.33 (0.22–0.47) |
| Other | 1 (0.8) | 492 (5.6) | 0.14 (0.01–0.69) |
| Insurance | |||
| Medicaid | 50 (40.3) | 1058 (12.1) | 5 (3.4–7.1) |
| Medicare | 35 (28.4) | 2528 (29) | 0.98 (0.5–1.4) |
| Private | 29 (23.1) | 4798 (55) | 0.35 (0.16–0.38) |
| Uninsured | 9 (8.2) | 344 (3.9) | 1.9 (0.91–3.7) |
| Primary gynecologic malignancy | 2.2 (1.5–3.1) | ||
| No | 59 (48) | 5873 (67.3) | |
| Yes | 62 (52) | 2855 (32.7) |
Features of terminated patients.
| Characteristics | N | % |
|---|---|---|
| Terminated patients | 123 | |
| Time of care (median days, range) | 144 (1–1625) | |
| Tobacco use | 61 | 49.6 |
| Drug abuse | 19 | 15.4 |
| Psychiatric diagnosis | 33 | 26.9 |
| Disability | 19 | 15.4 |
| Non-cancer diagnosis | ||
| Genital dysplasia | 20 | 16.2 |
| Pelvic/adnexal mass | 16 | 9.7 |
| Abnormal uterine bleeding | 10 | 9 |
| Endometrial hyperplasia | 3 | 2.2 |
| Fibroids/pain | 2 | 0.7 |
| Borderline ovarian tumour | 2 | 1.5 |
| Teratoma | 1 | 0.7 |
| Gestational trophoblastic disease | 4 | 3.3 |
| Reason for termination | ||
| Disruptive behavior | 13 | 10.6 |
| Drug abuse behavior | 3 | 2.4 |
| Missed appointments | 78 | 63.4 |
| Noncompliance to treatment | 29 | 23.6 |
Cancer diagnosis and relative risk of termination.
| Cancer site | Terminated patients N (%) | Retained patients N (%) | OR (95% CI) |
|---|---|---|---|
| Cervix | 27 (22) | 582 (6.7) | 3 (1.8–4.9) |
| Ovary/fallopian/peritoneal | 9 (7.3) | 693 (7.9) | 0.52 (0.24–1.0) |
| Uterus | 21 (17.1) | 1329 (15.2) | 0.57 (0.33–0.97) |
| Vagina/vulva | 5 (4.1) | 216 (2.5) | 1.1 (0.37–2.5) |